Mesoblast (MESO) Cash from Operations (2016 - 2023)
Mesoblast (MESO) posted quarterly Cash from Operations of 16278000.0 for Q2 2023, down 17.16% year-on-year from 19649568.38 in Q2 2022, and little changed on a QoQ basis from 16250000.0 in Q1 2023.
Mesoblast (MESO) Cash from Operations (2016 - 2023) Analysis & Trends
Mesoblast (MESO) has reported Cash from Operations for 8 consecutive years, with 16278000.0 the latest figure, recorded in Q2 2023.
- Quarterly Cash from Operations fell 17.16% year-over-year to 16278000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 63269000.0 (up 3.82% YoY) and the FY2025 annual result came in at 50000000.0, down 3.18% from the prior year.
- Cash from Operations steadied at 16278000.0 in Q2 2023 per MESO's latest filing, from 16250000.0 in the prior quarter.
- Over the last five years, Cash from Operations for MESO reached as high as 1330000.0 in Q4 2019 and fell as low as 30580000.0 in Q4 2020.
- A 5-year average of 17882333.33 and a median of 17326500.0 in 2021 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2020 — Cash from Operations plunged 2199.25% — and 2021, when it jumped 40.42%.
- Year by year, Cash from Operations stood at 1330000.0 in 2019, then tumbled by 2199.25% to 30580000.0 in 2020, then surged by 40.42% to 18219000.0 in 2021, then rose by 9.69% to 16454000.0 in 2022, then advanced by 1.07% to 16278000.0 in 2023.
- According to Business Quant data, Cash from Operations over the past three periods registered 16278000.0, 16250000.0, and 16454000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -16.28 Mn |
| Jun 30, 2023 | -16.28 Mn |
| Mar 31, 2023 | -16.25 Mn |
| Mar 31, 2023 | -16.25 Mn |
| Dec 31, 2022 | -16.45 Mn |
| Dec 31, 2022 | -16.45 Mn |
| Sep 30, 2022 | -14.29 Mn |
| Sep 30, 2022 | -14.29 Mn |
| Jun 30, 2022 | -13.89 Mn |
| Jun 30, 2022 | -13.89 Mn |
| Mar 31, 2022 | -15.47 Mn |
| Mar 31, 2022 | -15.47 Mn |
| Dec 31, 2021 | -18.22 Mn |
| Dec 31, 2021 | -18.22 Mn |
| Sep 30, 2021 | -18.20 Mn |
| Sep 30, 2021 | -18.20 Mn |
| Jun 30, 2021 | -18.92 Mn |
| Jun 30, 2021 | -18.92 Mn |
| Mar 31, 2021 | -24.47 Mn |
| Mar 31, 2021 | -24.47 Mn |